Zhengye Biotechnology Statistics
Share Statistics
Zhengye Biotechnology has 47.39M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 47.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 62,073 |
| FTD / Avg. Volume | 11.66% |
Short Selling Information
The latest short interest is 128.84K, so 0.27% of the outstanding
shares have been sold short.
| Short Interest | 128.84K |
| Short % of Shares Out | 0.27% |
| Short % of Float | 2.91% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Zhengye Biotechnology.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.37,
with a Debt / Equity ratio of 0.33.
| Current Ratio | 1.37 |
| Quick Ratio | 0.98 |
| Debt / Equity | 0.33 |
| Debt / EBITDA | 1.25 |
| Debt / FCF | 2.46 |
| Interest Coverage | 10.17 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $761,334.53 |
| Profits Per Employee | $113,154.68 |
| Employee Count | 278 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.4 |
Taxes
| Income Tax | 6.25M |
| Effective Tax Rate | 14.29% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is 0, so Zhengye Biotechnology's
price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 8.08 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 44.45 |
| Average Volume (20 Days) | 532,152 |
Income Statement
In the last 12 months, Zhengye Biotechnology had revenue of 211.65M
and earned 31.46M
in profits. Earnings per share was 0.
| Revenue | 211.65M |
| Gross Profit | 129.85M |
| Operating Income | 44.99M |
| Net Income | 31.46M |
| EBITDA | 72.1M |
| EBIT | 48.19M |
| Earnings Per Share (EPS) | 0 |
Full Income StatementBalance Sheet
The company has 15.07M in cash and 89.85M in
debt, giving a net cash position of -74.78M.
| Cash & Cash Equivalents | 15.07M |
| Total Debt | 89.85M |
| Net Cash | -74.78M |
| Retained Earnings | 38.38M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 48.18M
and capital expenditures -11.6M, giving a free cash flow of 36.58M.
| Operating Cash Flow | 48.18M |
| Capital Expenditures | -11.6M |
| Free Cash Flow | 36.58M |
| FCF Per Share | 0 |
Full Cash Flow StatementMargins
Gross margin is 61.35%, with operating and profit margins of 21.25% and 14.86%.
| Gross Margin | 61.35% |
| Operating Margin | 21.25% |
| Pretax Margin | 20.68% |
| Profit Margin | 14.86% |
| EBITDA Margin | 34.06% |
| EBIT Margin | 21.25% |
| FCF Margin | 17.29% |
